Could a common diabetes pill help people with rare lung disease breathe easier?
NCT ID NCT05179356
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug dapagliflozin (used for diabetes and heart failure) in 52 adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension. The goal was to see if it improves exercise capacity and heart function. Participants took the drug or a placebo for a period, then had tests like exercise stress and heart catheterization. The study is complete, and results will show if this drug can help manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
Copenhagen, 2100, Denmark